Journal of Clinical & Experimental OncologyISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Patient stratification and precision medicine in pancreatic cancer: A gene blood-signature for Gemcitabine treatment

David Piquemal


: J Clin Exp Oncol


Pancreatic Cancer (PC) kills 98% of those it afflicts and is one of the most lethal cancers worldwide. Patients diagnosed with PC have a poor prognosis partly because the cancer usually causes no symptoms early on, leading to metastatic disease at the time of diagnosis. The high mortality rate is partly due to the difficulty to diagnose and due to the lack of stratified patients to effective treatments. The capability of biomarkers to improve treatment and to reduce healthcare costs is potentially greater than in any other area of current medical research. Otherwise, healthcare stakeholders are facing two major issues: The reduction of global healthcare system expenditures and the growing need to improve the efficiency of therapies. Diagnostics are one of the most efficient solutions to respond to these needs by supporting physicians in the selection of the best treatment. From a without prior analysis and from a whole blood collection, from clinical trial phase III and based on a high throughput analysis of NGS data using the proprietary ACOBIOM genomics platform (big data system dedicated to biomarker discovery), we identified a set of genes in a pre-discovery phase. Using Real-Time PCR, candidate genes were selected for test significance and a gene expression based score was established. ACOBIOM developed a new in vitro diagnostic for patient stratification based on molecular analysis. The GemciTest® assay is an IVD associated with gemcitabine drug in PC treatment. GemciTest® is currently a prototype in an operational environment through a 15 Clinician Peer Network. This IVD is a quantitative real-time PCR assay and is intended to quantitatively aid in the determination of high probability progression- free survival and overall survival rates of patients diagnosed with pancreatic cancer and treated with gemcitabine as first-line therapy. In this context, ACOBIOM is always looking for new partnerships, public or private, the right way to really open the opportunity to develop safe/better solution in PC for the patient (bench-to-bedside), assisting physicians in routine patient care.


David Piquemal is the Co-Founder and Scientific Director of ACOBIOM Company. His main aim is to develop innovative methods and software to analyze, integrate and contextualize large-scale biological data in the fields of health, agronomy and environment. He has completed his PhD in Molecular Biology from the Institute of Human Genomic in the year 2000. His area of interests involves molecular biology, personalized medicine, translational medicine and bioinformatics.

E-mail: [email protected]

Track Your Manuscript

Media Partners